The paper, authored by Jamiu Adeniyi Yusuf and Ibrahim Ayodele Yusuf of the National Institute for Legislative and Democratic Studies in Abuja, Nigeria, introduces what the authors call a Sequential Gate Framework. Its central claim is deceptively simple: one-size-fits-all funding is ineffective because the risks facing a biotechnological venture change fundamentally as it matures. A policy instrument that works brilliantly for early-stage research can be useless, or even harmful, at the commercialization stage. By matching specific financial tools to three distinct development gates, the framework aims to give green biotech the kind of de-risked investment pathway that has historically propelled other deep-technology sectors to industrial scale.

To understand why the framework is needed, it helps to grasp what makes biotechnology financially unusual. The authors distinguish two intertwined categories of risk. Technical risk asks whether a technology will work reliably; market risk asks whether it will be profitable and adopted. In biotechnology, both are amplified because the core of the technology is living. Digital products, once proven, can often be replicated and distributed at almost no additional cost. Biotechnology operates in what scientists sometimes call wetware, systems built on living organisms, enzymes, and biological processes that respond unpredictably to changes in temperature, contamination, or raw material quality. Engineered microbes designed to break down waste or capture carbon may perform beautifully in a controlled laboratory environment and then lose efficiency when fed impure, real-world feedstock.

From an investor’s perspective, that unpredictability reads as unreliability, and unreliability raises the cost of capital. The problem is compounded by the dominance of existing grey infrastructure. Economies have been built over decades around conventional chemical, mechanical, and fossil-fuel-based systems that enjoy established supply chains, regulatory familiarity, and often direct subsidies. This creates what economists call path dependency, where past investments constrain present choices. Biotechnological alternatives must also overcome the green premium, the extra cost of choosing environmentally friendly technologies when their benefits, such as cleaner ecosystems or reduced emissions, are not fully reflected in market prices. Society gains, but the investor does not always see an immediate return. Worse, biotechnology lacks standardized benchmarks for measuring bio-risk, which makes institutional due diligence difficult and pushes capital toward safer, more familiar sectors.

The Sequential Gate Framework responds by dividing the biotechnological lifecycle into three gates, each with a defined risk profile, a targeted set of policy instruments, and measurable exit criteria tied to Technology Readiness Levels. The first is the R&D gate, where the dominant challenge is fundamental technical uncertainty. Private investors are typically reluctant to fund experiments that may take years to show any commercial promise, yet this is precisely where transformative ideas need the most support. The authors recommend direct public R&D subsidies to cover experiments, equipment, and skilled personnel, alongside patent box tax regimes that reduce taxes on income generated from intellectual property. A technology exits this gate only when it reaches a laboratory proof of concept, roughly TRL 3 to 4, and secures its intellectual property through patent filings.

The second gate is where most technologies die. At the demonstration stage, the challenge shifts from whether an idea works to whether it can be scaled. A bioreactor process proven in one-liter laboratory flasks may fail catastrophically at 10,000-liter pilot scale, where temperature fluctuations, shear stress, and unrefined feedstock introduce severe operational risks. The authors call the required tools public-private partnerships and first-loss guarantees. Under a first-loss arrangement, a public institution such as a government agency or development bank agrees to absorb the initial portion of any losses, which dramatically lowers the barrier for private investors. The exit criterion here is what the authors term technical bankability: stable, repeatable production at pilot scale, more than a hundred times laboratory volume, reaching TRL 6 to 7, with biological variance reduced to a margin acceptable to institutional underwriters.

The third and final gate confronts market risk. Even a proven technology must survive competition against cheap, fossil-fuel incumbents protected by decades of infrastructure and subsidy. The framework’s centerpiece instrument here is the Contract for Difference, or CfD, a mechanism already used in renewable energy markets. The government guarantees a strike price for the product; if the market price falls below that level, the government pays the difference, and if it rises above, the producer pays back the surplus. This delivers the revenue stability needed to secure long-term commercial loans. The authors also endorse Advanced Market Commitments, in which governments or large organizations pledge in advance to purchase a specified volume of bio-based materials or carbon capture services, creating guaranteed demand that justifies scale-up investment. Exit from this gate comes at TRL 8 to 9, when a technology achieves commercial price parity with fossil-fuel incumbents and sustains market demand without direct subsidies.

The paper illustrates the mechanics with a concrete case study: the commercialization of engineered microbes for enzymatic degradation of PET plastic waste. At the R&D gate, public grants fund genetic sequencing and initial bioreactor assays until the strains demonstrate a repeatable rate of plastic depolymerization. At the demonstration gate, a public-private partnership backed by a first-loss guarantee shields investors from a pilot bioreactor crash caused by feedstock contamination, and the technology achieves technical bankability once it shows steady, high-yield enzymatic throughput over a continuous operational cycle. At the market gate, a CfD establishes a guaranteed price for bio-recycled PET monomers, protecting the firm if virgin fossil-derived PET prices plummet and enabling the long-term borrowing required for true industrial scale.

Notably, the authors do not ignore the critiques of such interventionism. They engage directly with the crowding-out hypothesis, which warns that accessible public financing may displace private venture capital and misallocate resources toward inefficient technologies. Their mitigation is structural: public instruments must be designed as strict co-investments, acting as a catalyst rather than a replacement for private equity. They also acknowledge that long-term price guarantees are vulnerable to policy capture and rent-seeking, in which entrenched industrial actors lock in government support and shift technological risk onto taxpayers. Their remedy is time-bound sunset clauses and performance-based metrics, ensuring that state support decays predictably as technologies mature and functions as a temporary bridge rather than a permanent subsidy.

Looking forward, the authors highlight two cutting-edge accelerants. Digital Twins, virtual models that replicate real bioprocesses, combined with artificial intelligence, allow firms to predict scaling behavior before committing capital, turning what was once a black box into what they describe as something closer to a glass box. This directly attacks the information asymmetry between biotechnologists and institutional investors, lowering perceived risk and speeding commercialization. For emerging economies, where deep-tech venture capital markets are nearly absent and fiscal space is constrained, the framework pivots toward multilateral development banks, blended finance, sovereign green bonds, and facilities such as the Green Climate Fund, with regional demand aggregation through mechanisms like the African Continental Free Trade Area. The broader vision is a unified global bioeconomy taxonomy that would let projects be bundled into green bonds for institutional investors. If the authors are right, the fate of green biotechnology will be decided not in the laboratory but in the architecture of finance itself, and a synchronized, sequential de-risking strategy may be the missing blueprint that turns biological promise into planetary impact.

Subject of Research: A sequential policy framework for de-risking biotechnological investments in environmental sustainability

Article Title: From lab to ledger: a sequential policy framework for de-risking biotechnological investments in environmental sustainability

Article References: Yusuf, J. A., & Yusuf, I. A. (2026). From lab to ledger: a sequential policy framework for de-risking biotechnological investments in environmental sustainability. Frontiers in Environmental Engineering, 5, Article 1844952. https://doi.org/10.3389/fenve.2026.1844952

Image Credits: AI Generated

DOI: 10.3389/fenve.2026.1844952

Keywords: biotechnology, circular bioeconomy, Valley of Death, green finance, de-risking, Contracts for Difference, public-private partnerships, Digital Twins, technology readiness levels, environmental sustainability, first-loss guarantees, policy framework

NSF officials framed the investment as a direct attempt to close that gap and, in doing so, to protect the country’s competitive position in emerging technologies. “NSF invests in small businesses that bring the most innovative cutting-edge technologies to the market and society,” said Erwin Gianchandani, the foundation’s assistant director for Technology, Innovation and Partnerships. “By closing this gap that is known as the ‘valley of death,’ NSF aims to strengthen our commitment to translational research and further develop innovation ecosystems in the United States.” The valley of death, as the agency describes it, is the stage at which a new technological innovation has been substantially de-risked but has not yet been commercially proven, making it difficult to attract the funding or other support needed to achieve commercial viability. For deep-technology companies, whose products often require long development cycles, capital-intensive prototyping and regulatory navigation, that stage can be especially punishing. Unlike software ventures that can iterate quickly and cheaply, hardware-based and science-heavy startups frequently need years of sustained investment before their first meaningful revenue arrives.

The pilot will concentrate its support on companies that have already cleared significant federal hurdles. Its services are aimed at small businesses funded through NSF’s Small Business Innovation Research and Small Business Technology Transfer programs, specifically those that have completed Phase II or Phase IIB awards. These represent the later stages of the federal small-business pipeline, by which point a company has typically demonstrated the technical feasibility of its innovation and begun the hard work of translating it into a manufacturable, sellable product. Lesia Crumpton-Young, the TIP section head for small businesses, emphasized the economic stakes of that translation. “Many NSF-supported small businesses have the potential to become great commercial successes and contribute significantly to economic growth and job creation throughout the nation,” she said. “We want to support small businesses to overcome the hurdles common to commercializing deep technology innovations.” The program’s architects argue that without a deliberate bridge at this late stage, the substantial public investment already made in these companies through earlier SBIR and STTR awards risks being wasted.

At the helm of the new institute is Ivan Garibay, a professor of industrial engineering and management systems at UCF, who will serve as principal investigator. Garibay’s framing of the problem captures the technical distinction at the heart of the pilot’s mission. “A validated technology is a scientific achievement, but it isn’t yet a business,” he said. “Many NSF SBIR Phase II companies hold genuinely de-risked technologies, yet still lack the business expertise, infrastructure, and capital access to turn that validation into a viable company.” His description of NCTI’s role is deliberately complementary rather than duplicative. “NCTI completes that pipeline rather than duplicating any part of it: we coordinate the full continuum of federal resources, managing the handoffs from I-Corps customer discovery through to commercialization support, so each company knows where it stands and what comes next.” That coordination function, in which a single institute orchestrates the various federal programs a startup might otherwise have to navigate alone, is one of the pilot’s most distinctive design features.

The support package offered to participating companies is structured as what the program calls concierge-level individualized assistance. Each selected business will undergo a diagnostic triage to identify its specific commercialization bottlenecks, followed by the creation of an individualized commercialization plan tailored to its technology, market and funding situation. Companies will be paired with dedicated mentor teams and will receive curated introductions to potential customers, investors, industry partners and national laboratories, the latter offering access to specialized facilities and technical expertise that small startups could rarely afford on their own. Alongside this individualized support, the institute will provide direct commercialization funding, expert mentorship and connections to investors. The intent is to address simultaneously the three deficits that Garibay identified as the core of the valley of death: business expertise, infrastructure and access to capital. Peter Atherton, program director for NSF Small Business Innovation Research and Small Business Technology Transfer, described the approach as a bridge. “Providing a ‘bridge’ to support our late-stage NSF-funded companies will move their impactful innovation to the market more quickly and thereby benefit the national economy,” he said.

NCTI is not a sudden departure for UCF but rather the latest evolution of a commercialization pipeline the university has spent years constructing. Through initiatives including the Southeast Hub of NSF I-Corps, which trains researchers in customer discovery and lean startup methodology; NSF’s Accelerating Research Translation program, which builds institutional capacity to move academic discoveries toward practical use; and the Florida Semiconductor Engine, a regional coalition advancing the semiconductor industry, UCF has already helped researchers evaluate commercial opportunities, advance emerging technologies and strengthen regional innovation ecosystems. NCTI will build on that foundation while dramatically expanding its scope, extending UCF’s commercialization machinery to companies nationwide rather than confining it to Florida and the Southeast. University leadership has positioned the institute as a natural outgrowth of that trajectory. “NCTI builds on UCF’s growing national leadership in helping promising technologies become products, companies and economic growth,” said UCF President Alexander N. Cartwright, who added that Central Florida’s concentration of talent, industry and innovation positions the university to build a model with impact across the nation.

University research officials argue that the institute’s success will depend on the integration of the entrepreneurial infrastructure already in place at UCF. Winston Schoenfeld, the university’s vice president for research and innovation, described that integration as the anchor of the institution’s readiness. “UCF’s readiness to lead this national effort is anchored by our highly integrated entrepreneurial infrastructure critical in the ‘lab-to-market’ pipeline,” he said. “NCTI will ensure that federally funded technologies successfully transition into investor-ready commercial enterprises.” The phrase “investor-ready” is significant, because it identifies the precise handoff point where the valley of death typically opens. A company becomes investor-ready when its technology has been validated, its market has been defined, its team has been strengthened and its path to revenue is credible enough to attract private capital. Reaching that state requires exactly the combination of funding, mentorship and networking that the pilot intends to supply, and it is the state at which federal support has historically ended and private investment has historically been slow to begin.

Beyond its immediate services to individual companies, the pilot carries a broader experimental mandate: it is explicitly designed as a test of whether a scalable, long-term national model is feasible. Each stage of the program will be structured and independently evaluated, with the results determining whether NSF establishes a permanent program on the pilot’s foundation. That evaluative rigor reflects a growing recognition across the federal science establishment that commercialization outcomes can and should be measured as carefully as research outcomes. The factors, conditions and approaches that lead to the successful transition of deep-technology innovations into nationally impactful technologies will be systematically examined, generating evidence about which interventions, whether diagnostic triage, mentor teams, investor introductions or direct funding, actually move companies across the valley. If the pilot demonstrates measurable success, it could reshape how federal agencies support the late-stage development of science-based startups for years to come.

The stakes of the experiment extend well beyond the companies that participate. Deep technologies, which include advanced materials, quantum systems, biotechnology platforms, next-generation semiconductors and other science-intensive innovations, are widely viewed as critical to both economic competitiveness and national security, and competitors abroad have invested heavily in smoothing their own translation pipelines. When American startups fail in the valley of death, the underlying research, often funded by taxpayers through agencies like NSF, may be licensed abroad, shelved indefinitely or lost entirely, along with the jobs and industries it could have created. By intervening at the precise moment when public funding ends and private capital has not yet arrived, the NCTI pilot represents a deliberate attempt to keep that value inside the American innovation ecosystem. Whether a $20 million, two-year investment can meaningfully change the survival rates of deep-technology ventures remains to be seen, but the program’s designers are betting that coordinated, individualized, late-stage support can convert more laboratory-validated science into products, companies and economic growth, and that the lessons learned will justify a permanent national commitment.

Subject of Research: A $20 million NSF pilot program led by the University of Central Florida to help small businesses commercialize late-stage deep technologies and avoid the valley of death.

Article Title: NSF funds pilot program to support small businesses in accelerating commercialization of their late-stage deep-technology and avoid the “valley of death”

Article References: NSF funds pilot program to support small businesses in accelerating commercialization of their late-stage deep-technology and avoid the “valley of death”. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: NSF, valley of death, deep technology, commercialization, SBIR, STTR, University of Central Florida, NCTI, small business, technology transfer, innovation ecosystem, startup funding